To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€"25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop.

This book describes the premier organization for the performance and funding of biomedical research in the United States. By articulating events that occurred at the National Institutes of Health from 1991-2008, this volume also examines the leadership of directors Bernadine Healy, Harold Varmus and Elias Zerhouni. To conduct his research, Dr. Kastor interviewed more than 200 people currently working at the NIH, those who have left and those funded by the institute. In an engaging and dynamic prose style, Dr. Kastor presents his findings on the operations, problems, controversies, financies, politics and structure of the NIH. The book begins by examining topics such as the NIH's evaluation of grant funding, the argument between those who favor support of basic biomedical science versus clinical research, the inclusion of HIV/AIDS in the National Institute of Allergy and Infectious Diseases, and the unique features of the Clinical Center, the hospital of the NIH. The volume concludes with a review of the recent conflict of interest controversy, the NIH's response to recent budget constrictions and the role of the institute in the Obama administration.